top of page

The founder of Entos Pharmaceuticals describes trying to design a delivery vehicle that's better than AAV and LNPs by harnessing fusogens

  • Sep 13, 2024
  • 1 min read

John Lewis describes the limitations of AAV and LNPs, and how the Entos construct is meant overcome them. Plus, a summary of the company's pipeline, which includes obesity, cystic fibrosis, ocular diseases, and more.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

bottom of page